RecruitingNot ApplicableNCT06552637

Synchronized Diaphragmatic Stimulation in Symptomatic Heart Failure

RECOVER-HF - RandomizEd, Multi-Center, Double-Blinded Study of SynchrOnized Diaphragmatic Stimulation (SDS) for ImproVEment of Symptomatic Reduced Ejection Fraction Heart Failure


Sponsor

VisCardia Inc.

Enrollment

270 participants

Start Date

Apr 30, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

RECOVER HF is a clinical study designed to evaluate the safety and efficacy of Synchronized Diaphragmatic Stimulation delivered using the VisONE System in the treatment of patients with heart failure.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • NYHA classes II/III on optimal Guideline Directed Medical Therapy (GDMT)
  • QRS duration ≤ 130 ms
  • EF≤ 40%

Exclusion Criteria39

  • Baseline 6 minute walk test \> 500 meters or \< 200 meters
  • NT-proBNP\< 250 if on loop diuretics, or NT-proBNP \< 500 if not on loop diuretics
  • Supine resting heart rate \> 140 bpm
  • Systolic blood pressure \< 80 mmHg or \> 170 mmHg
  • Serum creatinine \> 2.5 mg/dL
  • Serum hepatic function 3x ULN
  • Any of the following within the previous 3 months: unstable angina, AMI, CABG, PTCA, CVA/TIA, persistent AF (\> 24 hours), symptomatic NSVT or DCCV
  • Any inotropic drug treatment within the previous 3 months
  • Bradycardia (heart rate \< 50 beats/min), atrial arrhythmias with rates \> 100 beats/min, sustained ventricular tachycardia or frequent ventricular ectopy \>10% present during screening
  • Significant uncontrolled symptomatic bradyarrhythmia, atrial fibrillation, unstable ventricular arrhythmias or frequent ventricular ectopy \> 10% documented within the previous 3 months
  • Reversible non-ischemic cardiomyopathy
  • Valvular disease requiring intervention within the next 12 months or presence of significant valve disease as determined by the site cardiologist as:
  • Greater than mild mitral valve stenosis
  • Greater than moderate mitral valve regurgitation
  • Greater than mild tricuspid valve stenosis
  • Greater than moderate-severe tricuspid valve regurgitation
  • Greater than moderate aortic stenosis
  • Greater than moderate aortic regurgitation
  • Greater than mild-moderate pulmonic stenosis
  • Greater than moderate pulmonic regurgitation
  • Severe primary pulmonary disease, including pulmonary arterial hypertension. PAP sys \>70 mmHg at rest
  • Severe COPD, other respiratory or lung diseases where FEV \< 50%
  • Presence of more than small pleural effusion or history of pleural drainage within the previous 6 months
  • Known history of diaphragmatic paralysis or suspicion confirmed by unilateral or bilateral elevation of the diaphragm on chest x-ray
  • Pericardial disease
  • Diabetic neuropathy
  • Existing diaphragmatic stimulation for respiration assist
  • Present LVAD, Baroreflex Activation Therapy, Cardiac Contractility Modulation or interatrial shunt devices; temporary mechanical cardiac assist devices (current or within the previous 3 months); or CRT that is indicated or implanted and functional
  • Contraindications to laparoscopic access to the diaphragm, as determined by the implanting physician
  • Known intra-abdominal pathology which could increase the risk of laparoscopic access to the diaphragm.
  • Previous open laparotomy within 1 year
  • Previous thoracic or abdominal organ transplant
  • Drug induced immuno-suppression
  • Body mass index \> 40
  • Enrollment in a concurrent investigation / clinical study
  • Having a life expectancy of \<1 year due to any condition
  • Pregnant or planning a pregnancy during the study period
  • Known allergies to implantable device materials
  • History of systemic infection requiring the use of intravenous antibiotics within the previous 3 months

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICESynchronized Diaphragmatic Stimulation

Implantable Pulse Generator system providing cardiac-gaited stimulation of the diaphragm and thereby influence cardiovascular properties relevant in heart failure.


Locations(1)

University of Pennsylvania

Philadelphia, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06552637


Related Trials